Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Covid-19 Vaccine Boosters: The Good, the Bad, and the Ugly Publisher



Rzymski P1, 2 ; Fal A2, 4 ; Flisiak R5 ; Gwenzi W6 ; Kelishadi R2, 7 ; Leemans A2, 8 ; Nieto JJ2, 9 ; Ozen A2, 10 ; Perc M2, 11, 12 ; Poniedzialek B1, 2 ; Sedikides C2, 13 ; Sellke F2, 14 ; Skirmuntt EC15 ; Stashchak A2, 16 Show All Authors
Authors
  1. Rzymski P1, 2
  2. Fal A2, 4
  3. Flisiak R5
  4. Gwenzi W6
  5. Kelishadi R2, 7
  6. Leemans A2, 8
  7. Nieto JJ2, 9
  8. Ozen A2, 10
  9. Perc M2, 11, 12
  10. Poniedzialek B1, 2
  11. Sedikides C2, 13
  12. Sellke F2, 14
  13. Skirmuntt EC15
  14. Stashchak A2, 16
  15. Rezaei N2, 17, 18
Show Affiliations
Authors Affiliations
  1. 1. Department of Environmental Medicine, Poznan University of Medical Sciences, Poznan, 60-806, Poland
  2. 2. Universal Scientific Education and Research Network (USERN), https//usern.tums.ac.ir, Tehran, 1417614411, Iran
  3. 3. Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, 02114, MA, United States
  4. 4. Collegium Medicum, Warsaw Faculty of Medicine, Cardinal Stefan Wyszynski University, Warsaw, 01-938, Poland
  5. 5. Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, 15-540, Poland
  6. 6. Biosystems and Environmental Engineering Research Group, Department of Agricultural and Biosystems Engineering, University of Zimbabwe, Mount Pleasant, P.O. Box MP167, Harare, Zimbabwe
  7. 7. Department of Pediatrics, Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, 8174673441, Iran
  8. 8. PROVIDI Lab, Image Sciences Institute, University Medical Center Utrecht, Utrecht, 3584 CX, Netherlands
  9. 9. Instituto de Matematicas, Universidade de Santiago de Compostela, Santiago de Compostela, 15782, Spain
  10. 10. Department of Pediatric Allergy and Immunology, Marmara University School of Medicine, Istanbul, 34854, Turkey
  11. 11. Faculty of Natural Sciences and Mathematics, University of Maribor, Maribor, 2000, Slovenia
  12. 12. Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, 404332, Taiwan
  13. 13. Center for Research on Self and Identity, School of Psychology, University of Southampton, Southampton, SO17 1BJ, United Kingdom
  14. 14. Alpert Medical School of Brown University, Division of Cardiothoracic Surgery, Rhode Island Hospital, Providence, 02905, RI, United States
  15. 15. Peter Medawar Building for Pathogen Research, Department of Zoology, University of Oxford, Oxford, OX1 3SY, United Kingdom
  16. 16. International Relations Office, Kharkiv National Medical University, Kharkiv, 61000, Ukraine
  17. 17. Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, 1417614411, Iran
  18. 18. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, 1417614411, Iran

Source: Vaccines Published:2021


Abstract

Pursuing vaccinations against COVID-19 brings hope to limit the spread of SARS-CoV-2 and remains the most rational decision under pandemic conditions. However, it does not come without challenges, including temporary shortages in vaccine doses, significant vaccine inequity, and questions regarding the durability of vaccine-induced immunity that remain unanswered. Moreover, SARS-CoV-2 has undergone evolution with the emergence of its novel variants, characterized by enhanced transmissibility and ability to at least partially evade neutralizing antibodies. At the same time, serum antibody levels start to wane within a few months after vaccination, ultimately increasing the risk of breakthrough infections. This article discusses whether the administration of booster doses of COVID-19 vaccines is urgently needed to control the pandemic. We conclude that, at present, optimizing the immunity level of wealthy populations cannot come at the expense of low-income regions that suffer from vaccine unavailability. Although the efficiency of vaccination in protecting from infection may decrease over time, current data show that efficacy against severe disease, hospitalization, and death remains at a high level. If vaccine coverage continues at extremely low levels in various regions, including African countries, SARS-CoV-2 may sooner or later evolve into variants better adapted to evade natural and vaccine-induced immunity, ultimately bringing a global threat that, of course, includes wealthy populations. We offer key recommendations to increase vaccination rates in low-income countries. The pandemic is, by definition, a major epidemiological event and requires looking beyond one’s immediate self-interest; otherwise, efforts to contain it will be futile. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Other Related Docs
38. Covid-19 Vaccination Challenges: A Mini-Review, Human Vaccines and Immunotherapeutics (2022)